Drug Targeting with Monoclonal Antibodies: A review

References

• Jain R K. Vascular and interstitial barriers to delivery of therapeutic agents in tumours. Cancer Metastasis Rev 1990; 9: 253–66
   PubMed Web of Science ®Google Scholar
• Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Reviews in Oncology 1989; 2: 113–21
   Google Scholar
• Vogel C W. Immunoconjugates: Antibody conjugates in radioimaging and therapy of cancer. Oxford University Press, New York 1987
   Google Scholar
• Frankel E. Immunotoxins. Kluwer Academic Publishers, Boston 1988
   Google Scholar
• Hermentin P, Seiler F R. Investigations with monoclonal antibody drug (anthracycline) conjugates. Behring Inst Mitt 1988; 82: 197–215
   Google Scholar
• Wawrzynczak E J, Davies A JS. Strategies in antibody therapy of cancer. Clin Exp Immunol 1990; 82: 189–93
   PubMedGoogle Scholar
• Blakey D C, Wawrzynczak E J, Wallace P M, Thorpe P E. Antibody toxin conjugates: A perspective. Prog Allergy 1988; 45: 50–90
   PubMedGoogle Scholar
• Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1986; 46: 3225–38
   PubMed Web of Science ®Google Scholar
• Herlyn M, Menard A, Koprowski H. Structure, function and clinical significance of human tumour antigens. J Natl Cancer Inst 1990; 82: 1883–9
   PubMed Web of Science ®Google Scholar
• Kronke M, Depper J M, Leonard W J, Vitetta E S, Waldmann T A, Greene W C. Adult T-cell leukemia: a potential target for ricin A chain immunotoxins. Blood 1985; 65: 1416–21
   PubMed Web of Science ®Google Scholar
• Trowbridge I S. Transferrin receptor as a potential therapeutic target. Prog Allergy 1988; 45: 121–46
   PubMedGoogle Scholar
• Epstein A L, Chen F-M, Taylor C R. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48: 5842–8
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer M JS, Clark M R, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-IH. Lancet 1988; 2: 1394–9
   PubMed Web of Science ®Google Scholar
• LoBuglio A F, Wheeler R H, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4
   PubMed Web of Science ®Google Scholar
• Colcher D, Bird R, Roselli M, et al. In vivo tumour targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191–7
   PubMed Web of Science ®Google Scholar
• Andrew S M, Pimm M V, Perkins A C, Baldwin R W. Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab), and Fab fragments in mice with colon carcinoma xenografts. Eur J Med 1986; 12: 168–75
   Google Scholar
• Greiner J W, Hand P H, Noguchi P, Fischer P B, Pestka S, Schlom J. Enhanced expression of tumour-associated antigens on human breast and colon tumour cells after recombinant human leukocyte a-interferon treatment. Cancer Res 1984; 44: 3208–14
   PubMed Web of Science ®Google Scholar
• Starling J J, Maciak R S, Hinson N A, Nichols C L, Briggs S L, Laguzza B C. In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumour-associated antigen defined by the KS1/4 monoclonal antibody. Cancer lmmunol Immunother 1989; 28: 171–8
   PubMedGoogle Scholar
• Schneck D W, Petersen B, Zimmerman J, Butler F, Dugan W. Phase 1 studies with a monoclonal antibody vinca conjugate (MC, KSI/4-DAVLB) in patients with adenocarcinomas. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, Calif, 1989
   Google Scholar
• Sivam G P, Comezoglu T, Manger R, Gray M A, Jarvis B B, Morgan A C. Immunoconjugates of Trichosthecenes and monoclonal antibody. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, Calif, 1989
   Google Scholar
• Youle R J, Greenfield L, Johnson V, Genetic G., Frankel A E. engineering of immunotoxins. Immunotoxins. Kluwer Acad Publ, Boston 1988; 113–22
   Google Scholar
• Bjorn M J, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985; 45: 1214–21
   PubMed Web of Science ®Google Scholar
• Stirpe F, Barbieri L. Ribosome-inactivating proteins up to date. FEBS Lett 1986; 195: 1–8
   PubMed Web of Science ®Google Scholar
• Engert A E, Martin G, Pfreundschuh M, et al. Antitumour effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumours in mice. Cancer Res 1990; 50: 2929–35
   PubMed Web of Science ®Google Scholar
• Could B J, Borowitz M J, Groves E S, et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989; 81: 775–81
   PubMed Web of Science ®Google Scholar
• Byers V S, Rodvien R, Grant K, et al. Phase 1 study of monoclonal antibody-ricin A chain immunotoxin Xomazyme-791 in patients with metastatic colon cancer. Cancer Res 1989; 49: 6153–60
   PubMed Web of Science ®Google Scholar
• Spitler L E, Mischak R, Scannon P. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Nucl Med Biol 1989; 16: 625–7
   Google Scholar
• Pai L H, Fitzgerald D J, Tepper M, Schacter B, Spitalny G, Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990; 50: 7750–3
   PubMed Web of Science ®Google Scholar
• Yu Y H, Crews J R, Cooper K, et al. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res 1990; 50: 3231–8
   PubMed Web of Science ®Google Scholar
• Pearson J W, Hedrick E, Fogler W E, et al. Enhanced therapeutic efficacy against an ovarian tumour xenograft of immunotoxins used in conjunction with recombinant a-interferon. Cancer Res 1990; 50: 6379–88
   PubMed Web of Science ®Google Scholar
• Le Doussal J M, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium III-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990; 50: 344–52
   Google Scholar
• Kurtzman S H, Russo A, Mitchell J B, et al. 212-Bismuth linked to an antipancreatic carcinoma antibody: Model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80: 449–52
   PubMedGoogle Scholar
• Barth R F, Soloway A H, Fairchild R G. Boron neutron capture therapy of cancer. Cancer Res 1990; 50: 1061–70
   PubMed Web of Science ®Google Scholar
• Bagshawe K D, Springer C J, Searle F, et al. A cytotoxic agent can be generated at cancer sites. Br J Cancer 1988; 58: 700–3
   PubMed Web of Science ®Google Scholar
• Senter P D, Schreiber G J, Hirschberg D L, Ashe S A, Hellstrom K E, Hellstrom I. Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989; 49: 5789–92
   PubMed Web of Science ®Google Scholar
• Kerr D E, Senter P D, Bumett W V, Hirschberg D L, Hellstrom I, Hellstrom K E. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumour cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 1990; 31: 202–6
   PubMed Web of Science ®Google Scholar
• Senter P D, Saulnier M G, Schreiber G J, et al. Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988; 85: 4842–6
   PubMed Web of Science ®Google Scholar
• Otaka M, Singhal A, Hakomori S. Antibody-mediated targeting of differentiation inducers to tumour cells: Inhibition of clonogenic cancer cell growth in vitro and in vivo. Biochem Biophys Res Commun 1989; 158: 202–8
   PubMedGoogle Scholar
• Borlinghaus K P, Fitzpatrick D A, Heindel N D, et al. Radiosensitizer conjugation to the carcinoma 19–9 monoclonal antibody. Cancer Res 1987; 47: 4071–5
   PubMedGoogle Scholar